RU2011124709A - ДВУЯДЕРНЫЕ ИНГИБИТОРЫ GlyT1 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ - Google Patents
ДВУЯДЕРНЫЕ ИНГИБИТОРЫ GlyT1 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ Download PDFInfo
- Publication number
- RU2011124709A RU2011124709A RU2011124709/04A RU2011124709A RU2011124709A RU 2011124709 A RU2011124709 A RU 2011124709A RU 2011124709/04 A RU2011124709/04 A RU 2011124709/04A RU 2011124709 A RU2011124709 A RU 2011124709A RU 2011124709 A RU2011124709 A RU 2011124709A
- Authority
- RU
- Russia
- Prior art keywords
- hydrogen
- carbon atoms
- organic residue
- independently selected
- possibly substituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 9
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 title claims 3
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 28
- 239000001257 hydrogen Substances 0.000 claims abstract 28
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 26
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 25
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract 17
- 150000002367 halogens Chemical class 0.000 claims abstract 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 16
- 125000001424 substituent group Chemical group 0.000 claims abstract 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract 6
- 229910052717 sulfur Chemical group 0.000 claims abstract 6
- 239000011593 sulfur Chemical group 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 5
- 239000001301 oxygen Chemical group 0.000 claims abstract 5
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 4
- 150000002825 nitriles Chemical class 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 3
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 208000028017 Psychotic disease Diseases 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 2
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000035548 disruptive behavior disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical group N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14103008P | 2008-12-29 | 2008-12-29 | |
| US61/141,030 | 2008-12-29 | ||
| PCT/US2009/069716 WO2010078348A1 (en) | 2008-12-29 | 2009-12-29 | 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011124709A true RU2011124709A (ru) | 2013-02-10 |
Family
ID=42310195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011124709/04A RU2011124709A (ru) | 2008-12-29 | 2009-12-29 | ДВУЯДЕРНЫЕ ИНГИБИТОРЫ GlyT1 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8497289B2 (enExample) |
| EP (1) | EP2381941A4 (enExample) |
| JP (1) | JP2012514006A (enExample) |
| KR (1) | KR20110117087A (enExample) |
| CN (1) | CN102271677A (enExample) |
| AU (1) | AU2009335120A1 (enExample) |
| BR (1) | BRPI0923878A2 (enExample) |
| CA (1) | CA2747602A1 (enExample) |
| IL (1) | IL213541A0 (enExample) |
| MX (1) | MX2011006845A (enExample) |
| RU (1) | RU2011124709A (enExample) |
| WO (1) | WO2010078348A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| BR112016025910A8 (pt) * | 2014-05-06 | 2021-07-13 | Univ Northwestern | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos |
| US9987242B2 (en) | 2015-05-05 | 2018-06-05 | Northwestern University | Treatment of Levodopa-induced Dyskinesias |
| CR20210545A (es) * | 2019-05-01 | 2021-12-23 | Boehringer Ingelheim Int | Formas sólidas de un inhibidor de glyt1 |
| CA3188340A1 (en) | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairement associated with schizophrenia |
| KR20230088761A (ko) | 2020-10-13 | 2023-06-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 재가공하는 방법 |
| JP2025528779A (ja) | 2022-08-09 | 2025-09-02 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｐｄｅ４ｂ阻害剤及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981168A (en) * | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| EA009903B1 (ru) * | 2003-10-14 | 2008-04-28 | Пфайзер Продактс Инк. | Бициклические [3.1.0] производные в качестве ингибиторов переносчиков глицина |
| AU2005317846B2 (en) * | 2004-12-21 | 2011-12-08 | Merck Sharp & Dohme Limited | Piperidine and azetidine derivatives as GlyT1 inhibitors |
| US20080319043A1 (en) * | 2005-05-03 | 2008-12-25 | Mohammad Salman | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists |
| GB0523998D0 (en) * | 2005-11-25 | 2006-01-04 | Merck Sharp & Dohme | Therapeutic agents |
| CL2007002809A1 (es) * | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
-
2009
- 2009-12-29 EP EP09837121A patent/EP2381941A4/en not_active Withdrawn
- 2009-12-29 US US12/648,972 patent/US8497289B2/en not_active Expired - Fee Related
- 2009-12-29 MX MX2011006845A patent/MX2011006845A/es not_active Application Discontinuation
- 2009-12-29 CA CA2747602A patent/CA2747602A1/en not_active Abandoned
- 2009-12-29 BR BRPI0923878-6A patent/BRPI0923878A2/pt not_active IP Right Cessation
- 2009-12-29 AU AU2009335120A patent/AU2009335120A1/en not_active Abandoned
- 2009-12-29 RU RU2011124709/04A patent/RU2011124709A/ru not_active Application Discontinuation
- 2009-12-29 KR KR1020117016603A patent/KR20110117087A/ko not_active Withdrawn
- 2009-12-29 CN CN2009801530939A patent/CN102271677A/zh active Pending
- 2009-12-29 WO PCT/US2009/069716 patent/WO2010078348A1/en not_active Ceased
- 2009-12-29 JP JP2011543717A patent/JP2012514006A/ja active Pending
-
2011
- 2011-06-14 IL IL213541A patent/IL213541A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012514006A (ja) | 2012-06-21 |
| KR20110117087A (ko) | 2011-10-26 |
| CA2747602A1 (en) | 2010-07-08 |
| US20100256192A1 (en) | 2010-10-07 |
| BRPI0923878A2 (pt) | 2015-07-28 |
| IL213541A0 (en) | 2011-07-31 |
| AU2009335120A1 (en) | 2011-07-07 |
| WO2010078348A1 (en) | 2010-07-08 |
| CN102271677A (zh) | 2011-12-07 |
| US8497289B2 (en) | 2013-07-30 |
| MX2011006845A (es) | 2011-08-04 |
| EP2381941A4 (en) | 2012-08-01 |
| EP2381941A1 (en) | 2011-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| UA102837C2 (ru) | Производные азабициклических карбоксамидов, их получение и их применение в терапии | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| MX2009003882A (es) | Compuestos heteroaromaticos biciclicos. | |
| EA201171211A1 (ru) | Производные оксадиазола | |
| EA200600323A1 (ru) | γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| JP2012514006A5 (enExample) | ||
| AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| PH12014500775A1 (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| PH12012500867A1 (en) | Ethynyl derivatives | |
| PH12016500427A1 (en) | Ethynyl derivatives | |
| AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
| BR112013008675A2 (pt) | métodos e composições para o tratamento de diabetes e dislipidemia | |
| EA200971045A1 (ru) | Арилокси- и гетероарилоксизамещенные тетрагидробензазепины и их применение для блокировки обратного захвата норэпинефрина, допамина и серотонина | |
| EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
| MY165141A (en) | Pyrazolidin-3-one derivatives | |
| NO20064892L (no) | Heterosykliske fenylpropan-2-olderivater og relaterte forbindelser som modulatorer av norepinefrin (NE) og serotonin (5-HT) aktivitet og monoamin-gjenopptak for behandling av | |
| EA201270421A1 (ru) | 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт | |
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). | |
| EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина | |
| MX354414B (es) | Derivados de etinilo como moduladores del receptor glutamato metabotropico. | |
| EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| PH12015500261A1 (en) | Arylethynyl pyrimidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140314 |